Dr. Joshua Sabari discusses the changing treatment landscape for patients with NSCLC and EGFR mutations.
Follow @JanssenGlobal for more news and information during WCLC 2020
Thank you for visiting the Janssen Oncology newsroom to learn more about our research that will be presented at the International Association for the Study of Lung Cancer’s (IASLC) virtual 2020 World Conference on Lung Cancer Singapore (WCLC).
Janssen Oncology has eight company-sponsored presentations at WCLC highlighting our dedication to advancing science and delivering new medicines for patients with non-small cell lung cancer (NSCLC).
You can learn more about what Janssen is doing to address the COVID-19 pandemic here.
Leadership Perspectives
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are steadfast in our commitment to eradicate cancer. One of the many ways we demonstrate this commitment is by investing in research to develop treatments for patients who face significant unmet medical needs.
At this week's virtual WCLC 2020, Janssen will feature eight presentations focused on improving outcomes for patients with genetically-defined non-small cell lung cancer, many of whom have limited treatment options. Through our robust clinical program, our goal is to redefine the treatment landscape for these patients and reimagine care to transform the trajectory of lung cancer around the world.
We are privileged to work with a team of leading scientists dedicated to making cancer a preventable, manageable and curable condition. Thank you for visiting Janssen's WCLC 2020 virtual newsroom to learn more about our latest advancements in lung cancer.
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC.
Serge Messerlian
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.